For the LTBMC experiments we used 3 BM-MSC from PV patients and 4 samples from ET patients, we observed that ET-MSC showed more capacity to maintain the HD-CD34+ cells, without differences between the groups. This evidence concerns the gene CD34 and essential thrombocythemia.